NMT Medical, Inc. (NASDAQ: NMTI), an precocious medical perseverance science company that designs, develops, manufactures and markets proprietary implant technologies that allow interventional cardiologists to treat structural heart disease through minimally invasive, catheter-based procedures, announced that it has orthodox precursive results for CLOSURE I, its patent foramen ovale (PFO)/stroke and fugacious ischemic attack (TIA) trial in the U.S. CLOSURE I is the first fully enrolled, randomized clinical trial to evaluate the effectiveness of PFO therapy


the aa™ - official sitejoin & save up to 34% today with the uk's largest mishap company!www.theaa.com
intensive rehabilitationpatient centred programs for spinal cord in preventing circular strokes and TIAs...

More: - Read the rest here